Lixin Qiu

Lixin Qiu

Auto-generated profile, based on publicly available information

Lixin Qiu

Department of Oncology, Shanghai Medical College Fudan University Shanghai China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2023 in International Journal of Cancer
Verified
Journal Article
Closed access
LCLei Cheng
Lei Cheng
YCYuanyuan Chang
Yuanyuan Chang
ZXZuguang Xia
Zuguang Xia
YLYizhen Liu
Yizhen Liu
XLXiao Liu
Xiao Liu
LQLixin Qiu
Lixin Qiu

20 May 2021 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
WGWeijian Guo
Weijian Guo
XZXiaodong Zhu
Xiaodong Zhu
MHMingzhu Huang
Mingzhu Huang
YWYusheng Wang
Yusheng Wang
ZCZhiyu Chen
Zhiyu Chen
XWXiaoFeng Wang
XiaoFeng Wang
4014 Background: At present, there is no standard chemotherapy regimen for advanced gastric cancer (AGC), and there is no consensus whether the three-drug combination is better than two-drug combination in first-line treatment. Both of XELOX regimen and EOX regimen are widely recommended as firs-line chemotherapy regimens for AGC. In this EXELOX trial, we aimed to compare the efficacy and safety of EOX and XELOX regimens. Methods: EXELOX is an open-label, multicenter, prospective, randomized phase III trial that enrolled 448 previously untreated patients with histologically confirmed advanced gastric adenocarcinoma from 7 hospitals in China. Patients were randomly assigned (1:1) to receive XELOX regimen (oxaliplatin 130mg/m2 d1; xeloda 1000mg/m2 bid d1-14) or EOX regimen (epirubicin 50mg/m2 d1; oxaliplatin 130mg/m2 d1; xeloda 1000mg/m2 bid d1-14) in this study. Treatment was repeated every 3 weeks until disease progression, intolerable toxicity, patient death, withdrawal of informed consent, or up to eight cycles, followed by xeloda single-agent maintenance. We stratified randomization by Eastern Cooperative Oncology Group status, extent of disease(locally advanced/metastatic) and clinical trial center. Patients and clinicians were not masked to the allocated treatment. The primary endpoint was progression-free survival (PFS) on an intention-to-treat basis with a non-inferiority upper margin of 1.3 for the hazard ratio (HR). The clinical trial was a non-inferiority study that was registered with ClinicalTrials.gov, Number NCT02395640. The study is ongoing, but no longer recruit new participants. Results: Between Apr 10,2015 and Aug 20,2020, a total of 448 AGC patients were randomized to receive XELOX (n = 222) or EOX (n = 226). In ITT basis, the median PFS was 5.0 months (95%CI 4.5-6.0) in XELOX group and 5.5 months (95%CI 5.0-6.0) in EOX group (HR 0.989, 95%CI 0.812-1.203; Pnon-inferiority= 0.0032). In Per-protocol population (n = 428), the median PFS was 5.0 months (95%CI 5.0-6.0) in XELOX group and 5.5 months (95%CI 5.0-6.0) in EOX group (HR 0.983, 95%CI 0.807-1.198; Pnon-inferiority= 0.0028). The incidence of grade 3-4 adverse events (AEs) was 42.2% (90/213) in XELOX group and 72.5(156/215) in EOX group (p= 0.001). The most common grade 3-4 AEs were neutropenia (affecting 13.1% (28/213) in XELOX group and 48.4%(104/215) in EOX group (p= 0.000). The incidence of chemotherapy dose reduction was 35% (75/213) in XELOX group and 55% (120/215) in EOX group(p= 0.009). One treatment-related death (lung infection) was observed in EOX group, and none in XELOX group. Conclusions: XELOX regimen is noninferior to EOX regimen in PFS with a better safety profile as first-line treatment for AGC patients, therefore XELOX is a more favorable choice and might be one of the standard first-line chemotherapy regimens. Clinical trial information: NCT02395640.

20 May 2019 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
XZXiaoying Zhao
Xiaoying Zhao
WGWeijian Guo
Weijian Guo
ZCZhiyu Chen
Zhiyu Chen
XZXiaowei Zhang
Xiaowei Zhang
XZXiaodong Zhu
Xiaodong Zhu
WLWenhua Li
Wenhua Li
4054 Background: Paclitaxel is a microtubule stabilizing agent that has been the standard second line chemotherapy in the treatment of advanced gastric cancer. This study was designed to find out the clinical outcome of paclitaxel plus raltitrexed regimen as second line treatment in MGC patients. Methods: In an open, randomized, multi centers phase II clinical trial , 148 patients were randomly assigned and treated with either RP (raltitrexed 3 mg/m2 d1 and paclitaxel 135mg/m2 d1,3w) or P (paclitaxel 135mg/m2 d1,3w) as second-line palliative chemotherapy. The primary endpoint is PFS, secondary endpoint is ORR, OS and safety. Results: In 148 randomly assigned and treated patients (RP = 73; P = 75), the majority of patients were males (94 vs. 54). Progression free survival has a tendency to be prolonged with RP versus P (2.7m vs. 1.7m, p = 0.148). Overall survival also has a tendency to be prolonged with RP versus P (10.2m vs. 6.1m, p = 0.140). Overall response rate was equal with RP versus P (6.8% vs.4.0%, p = 0.72). DCR in the RP group was 56.2%, P group was 36.0%. Grade 3 to 4 treatment-related adverse events occurred in 36.2% (RP) v 28.2% (P) of patients. Frequent grade 3 to 4 toxicities for RP v P were: neutropenia (11.0% v 4.0%), anemia (1.4% v 4.0%), thrombocytopenia (1.4% v 5.3%), and all grade peripheral neurotoxicity (12.3% v 17.3%),all grade elevated aminotransferase (27.4% v 14.1%). Subgroup analysis shows if the disease combined with ascites or peritoneal involved , OS of RP regimen is more longer (p = 0.05). Conclusions: Second-line palliative chemotherapy with paclitaxel plus raltitrexed provides a tendency to prolong PFS and OS, and the patients with ascites or peritoneal involved may get benifits from combined chemotherapy, which needs to be confirmed by larger sample studies. Clinical trial information: NCT02072317.

30 March 2020 in Theory and Practice of Social Science
Verified
Journal Article
Closed access
JZJuntian Zhou
Juntian Zhou
LQLixin Qiu
Lixin Qiu
Based on the guiding ideology and core concept of the emerging engineering, this paper analyzes the contradiction between supply and demand in the cultivation of industrial engineering professionals from the perspective of social demand through the questionnaire, and put forward the path of personnel Training of industrial engineering specialty of "two platforms and three centers" integrating industry and education based on "s-t-c" model, the level of industrial engineering talents training can be comprehensively improved through the measures of double-wheel drive, multi-dimensional construction, integration of industry and education and cross-boundary training of colleges and enterprises. Finally, the paper puts forward the guarantee measures for the construction and reform of industrial engineering teaching system.

15 May 2026 in Molecular Carcinogenesis
Verified
Journal Article
Closed access
PDF file
GZGuang Zeng
Guang Zeng
GLGuoqiang Lu
Guoqiang Lu
BHBeiping Hu
Beiping Hu
MXMidie Xu
Midie Xu
GLGuanlin Li
Guanlin Li
QWQingyi Wei
Qingyi Wei